A systematic review and meta-regression published in eClinicalMedicine (November 2025) confirmed what a lot of GLP-1 users have experienced firsthand: weight, HbA1c, and blood pressure all rebounded after stopping GLP-1 therapy
At best, it might be plain sterile water mislabeled as bacteriostatic
Discontinuation due to adverse events was 8.4% on CagriSema vs 3% on placebo
In NAFLD models, upregulation of FMO1 and ferroptosis markers contributes to hepatic lipid accumulation, disrupting lipid metabolism and accelerating disease progression (57)
In the SURPASS-2 trial published in the New England Journal of Medicine, participants treated with tirzepatide (5 mg, 10 mg, or 15 mg weekly) experienced reductions in fasting triglycerides from baseline over 40 weeks, with greater reductions generally seen at higher doses